Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biminne is a multi-herb formulation developed by G & W Australia for the symptomatic relief of allergic diseases, particularly allergic rhinitis (hay fever) and sinusitis. The formulation consists of extracts from eleven traditional Chinese herbs, including *Scutellaria baicalensis*, *Astragalus membranaceus*, and *Ginkgo biloba*. It is administered orally, typically in capsule form, and functions by improving immune regulation, reducing allergy-related antibodies (specifically total serum IgE), and controlling inflammation. Clinical trials conducted by researchers at the University of Sydney have demonstrated its efficacy in treating perennial allergic rhinitis, with evidence suggesting that the therapeutic benefits can persist for up to one year following the completion of treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biminne.